Loading the section
Closing prices for 09 October 2026
Next earnings report: 03 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Rhythm Pharmaceuticals, Inc. trades on Nasdaq under the ticker RYTM. The company belongs to the Health care sector. The trading history on this page starts on 09 October 2017.
Over the past 52 weeks RYTM has traded between 74.50 $ and 122.20 $. As of 09 October 2026 the price stood 34.13 % of the way from the 52-week low to the high.
Over one year RYTM shares fell 9.43 %; over six months they rose 7.57 %. Volatility over 90 days is 38.14 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 28.2, above the sector median of 3.9. Price to book is 49.7, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 89.67 | 93.35 | 89.49 | 90.78 | 1M |
| 08 October 2026 | 89.05 | 90.94 | 87.01 | 89.64 | 1M |
| 07 October 2026 | 90.77 | 91.37 | 88.23 | 88.45 | 939,400 |
| 06 October 2026 | 92.55 | 94.47 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Rhythm Pharmaceuticals, Inc. (RYTM) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 189.8m $, net income was -196.5m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:222 BERKELEY STREET 12TH FLOOR, BOSTON, MA, 02116, US
Rhythm Pharmaceuticals, Inc. reported revenue of 217M $ and a net loss of 203M $ over the last four quarters. Net margin is −93.33 %. Revenue changed by +58.67 % year over year. Earnings per share are −3.13 $. Market capitalisation is 6.1B $.
RYTM has a return on equity of −164.91 %, below the sector median of −41.68 %. Return on assets is −45.82 %, below the sector median of −32.11 %. Operating margin is −90.89 %, below the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 90.07 |
| 90.77 |
| 992,900 |
| 05 October 2026 | 93.95 | 94.41 | 89.53 | 92.45 | 1M |
| 02 October 2026 | 94.97 | 95.32 | 92.66 | 92.83 | 503,500 |
| 01 October 2026 | 95.34 | 96.48 | 93.00 | 93.41 | 850,600 |
| 30 September 2026 | 96.67 | 97.37 | 95.10 | 95.22 | 737,200 |
| 29 September 2026 | 97.92 | 98.91 | 94.51 | 95.71 | 810,900 |
| 28 September 2026 | 98.01 | 99.15 | 95.27 | 98.56 | 897,400 |
| 25 September 2026 | 98.41 | 99.45 | 96.35 | 98.66 | 864,300 |
| 24 September 2026 | 97.73 | 99.28 | 95.38 | 98.31 | 730,800 |
| 23 September 2026 | 99.27 | 100.02 | 96.47 | 98.24 | 696,400 |
| 22 September 2026 | 100.44 | 101.85 | 98.69 | 99.27 | 499,900 |
| 21 September 2026 | 98.47 | 100.76 | 97.54 | 98.83 | 613,600 |
| 18 September 2026 | 99.36 | 99.36 | 96.88 | 97.71 | 1M |
| 17 September 2026 | 101.17 | 102.00 | 98.80 | 99.02 | 617,700 |
| 16 September 2026 | 97.69 | 100.85 | 97.06 | 98.01 | 921,400 |
| 15 September 2026 | 101.66 | 101.66 | 96.14 | 96.77 | 914,300 |
| 14 September 2026 | 105.27 | 105.93 | 101.09 | 102.44 | 789,700 |